Targeting Aurora A kinase activity with the investigational agent alisertib increases the efficacy of cytarabine through a FOXO‐dependent mechanismKevin R. Kelly, Jennifer S. Carew, Jeffrey Ecsedy et al.|International Journal of Cancer|2012Cited by 53
Antitumor activity of inhibiting SYK kinase with TAK-659, an investigational agent, in DLBCL models.Jessica J. Huck, Karuppiah Kannan, Rachael Brake et al.|Journal of Clinical Oncology|2014Cited by 6
TAK-659 in combination with NKTR-214 and anti-PD-1 therapy leads to complete and sustained tumor regression and immune memory in pre-clinical syngeneic models.Jie Yu, Jonathan Zalevsky, Jessica Huck Sappal et al.|Journal of Clinical Oncology|2018Cited by 0